Immunogenicity of Streptococcus Pneumoniae Type 14 Capsular Polysaccharide: Influence of Carriers and Adjuvants on Isotype Distribution

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1991 Aug 1

PMID 1855991

Citations 7

Authors

J H van de Wijgert

A F Verheul

H Snippe

I J Check

R L Hunter

Affiliations

Soon will be listed here.

Abstract

This project investigated the effects of novel carriers and adjuvants on the isotype of murine immunoglobulin G (IgG) antibody to pneumococcal capsular polysaccharide type 14 (S14PS). S14PS conjugated to bovine serum albumin induced a weak antibody response which was 100% IgG1 following injection without adjuvant. The same polysaccharide conjugated to flagella of Salmonella typhi induced an antibody response which was 88% IgG3. S14PS-bovine serum albumin was injected with block copolymer L121 or Quil A in squalane-in-water emulsions. The copolymer L121 was at least as effective as Quil A or complete Freund adjuvant in inducing IgG antibodies. IgG1 was the dominant subclass for all. Addition of monophosphoryl lipid A, but not the threonyl derivative of muramyl dipeptide or nontoxic Rhodopseudomonas sphaeroides lipopolysaccharide, to copolymer L121 increased production of the IgG2a, IgG2b, and IgG3 subclasses. S14PS-flagella with copolymer L121 induced higher titers with a markedly altered isotype distribution: 13% IgG1, 52% IgG2a, 6% IgG2b, and 29% IgG3. Monophosphoryl lipid A added to L121 reduced IgG1 antibody to 5%, but increased IgG2a antibody to 14%, IgG2b antibody to 3%, and IgG3 antibody to 78%. These studies demonstrate that both the carrier and the adjuvant can influence the titer and isotype distribution of antipolysaccharide antibody responses.

Citing Articles

Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.

Micoli F, Stefanetti G, MacLennan C Front Mol Biosci. 2023; 10:1201693.

PMID: 37261327 PMC: 10227950. DOI: 10.3389/fmolb.2023.1201693.

Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.

Lefeber D, Benaissa-Trouw B, Vliegenthart J, Kamerling J, Jansen W, Kraaijeveld K Infect Immun. 2003; 71(12):6915-20.

PMID: 14638780 PMC: 308892. DOI: 10.1128/IAI.71.12.6915-6920.2003.

Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Yang C, Collins W, Sullivan J, Kaslow D, Xiao L, Lal A Infect Immun. 1998; 67(1):342-9.

PMID: 9864235 PMC: 96316. DOI: 10.1128/IAI.67.1.342-349.1999.

New vaccines for the prevention of pneumococcal infections.

Kayhty H, Eskola J Emerg Infect Dis. 1996; 2(4):289-98.

PMID: 8969245 PMC: 2639933. DOI: 10.3201/eid0204.960404.

Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

AlonsoDeVelasco E, Verheul A, Verhoef J, Snippe H Microbiol Rev. 1995; 59(4):591-603.

PMID: 8531887 PMC: 239389. DOI: 10.1128/mr.59.4.591-603.1995.

References

Verheul A, Versteeg A, Westerdaal N, van Dam G, Jansze M, Snippe H . Measurement of the humoral immune response against Streptococcus pneumoniae type 14-derived antigens by an ELISA and ELISPOT assay based on biotin-avidin technology. J Immunol Methods. 1990; 126(1):79-87. DOI: 10.1016/0022-1759(90)90014-m. View

Coon J, Hunter R . Properties of conjugated protein immunogens which selectively stimulate delayed-type hypersensitivity. J Immunol. 1975; 114(5):1518-22. View

Briles D, CLAFLIN J, Schroer K, Forman C . Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature. 1981; 294(5836):88-90. DOI: 10.1038/294088a0. View

Salimath P, Weckesser J, Strittmatter W, Mayer H . Structural studies on the non-toxic lipid A from Rhodopseudomonas sphaeroides ATCC 17023. Eur J Biochem. 1983; 136(1):195-200. DOI: 10.1111/j.1432-1033.1983.tb07726.x. View

Takehara H, Perini A, Da Silva M, Mota I . Trypanosoma cruzi: role of different antibody classes in protection against infection in the mouse. Exp Parasitol. 1981; 52(1):137-46. DOI: 10.1016/0014-4894(81)90069-2. View

Aplin J, WRISTON Jr J . Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids. CRC Crit Rev Biochem. 1981; 10(4):259-306. DOI: 10.3109/10409238109113601. View

Hunter R, Strickland F, Kezdy F . The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J Immunol. 1981; 127(3):1244-50. View

Hirschmann J, Lipsky B . Pneumococcal vaccine in the United States. A critical analysis. JAMA. 1981; 246(13):1428-32. View

Perlmutter R, Hansburg D, Briles D, Nicolotti R, Davie J . Subclass restriction of murine anti-carbohydrate antibodies. J Immunol. 1978; 121(2):566-72. View

10.

Takayama K, Olsen M, Datta P, Hunter R . Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors. Vaccine. 1991; 9(4):257-65. DOI: 10.1016/0264-410x(91)90109-j. View

11.

Hunter R, Olsen M, Buynitzky S . Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody. Vaccine. 1991; 9(4):250-6. DOI: 10.1016/0264-410x(91)90108-i. View

12.

Ukei S, Iida J, Shiba T, Kusumoto S, Azuma I . Adjuvant and antitumour activities of synthetic lipid A analogues. Vaccine. 1986; 4(1):21-4. DOI: 10.1016/0264-410x(86)90093-9. View

13.

Le Garrec Y . Immunomodifiers of bacterial origin. Comp Immunol Microbiol Infect Dis. 1986; 9(2-3):137-41. DOI: 10.1016/0147-9571(86)90005-6. View

14.

Baker P, Hiernaux J, Fauntleroy M, STASHAK P, PRESCOTT B, Cantrell J . Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect Immun. 1988; 56(12):3064-6. PMC: 259701. DOI: 10.1128/iai.56.12.3064-3066.1988. View

15.

Baker P, Hiernaux J, Fauntleroy M, PRESCOTT B, Cantrell J, Rudbach J . Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A. Infect Immun. 1988; 56(5):1076-83. PMC: 259765. DOI: 10.1128/iai.56.5.1076-1083.1988. View

16.

KENNEY J, Hughes B, Masada M, Allison A . Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J Immunol Methods. 1989; 121(2):157-66. DOI: 10.1016/0022-1759(89)90156-7. View

17.

Tomai M, Johnson A . T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J Biol Response Mod. 1989; 8(6):625-43. View

18.

Zigterman G, Schotanus K, Ernste E, van Dam G, Jansze M, Snippe H . Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates. Infect Immun. 1989; 57(9):2712-8. PMC: 313516. DOI: 10.1128/iai.57.9.2712-2718.1989. View

19.

Briles D, Forman C, Horowitz J, Volanakis J, Benjamin Jr W, McDaniel L . Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun. 1989; 57(5):1457-64. PMC: 313299. DOI: 10.1128/iai.57.5.1457-1464.1989. View

20.

Verheul A, Versteeg A, De Reuver M, Jansze M, Snippe H . Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect Immun. 1989; 57(4):1078-83. PMC: 313232. DOI: 10.1128/iai.57.4.1078-1083.1989. View